AmerisourceBergen Drug Corporation

Amerisourcebergen Drug Corporation is the franchisor behind the Good Neighbor Pharmacy Premier Pharmacies program. It is a Delaware corporation with roots reaching back to 1871, when Lucien Napoleon Brunswig began a pharmacist apprenticeship. The modern company formed through the 2001 merger of AmeriSource Health Corporation and Bergen Brunswig Corporation. Bergen Brunswig grew from Emil P. Martini's 1947 creation of Bergen Drug Company and his 1969 acquisition of Brunswig Drug Corporation. On August 30, 2023, the parent company completed its rebranding to Cencora, Inc., which trades on the NYSE under ticker COR and is headquartered in Conshohocken, Pennsylvania. Cencora employs approximately 51,000 people as of 2025, operates across 75 countries, and reported $294.0 billion in fiscal year 2024 revenue, an increase of 12.1% from the prior year. Eligible independent pharmacy operators can convert existing pharmacies or establish new retail locations as Good Neighbor Pharmacy Premier Pharmacies. The key question for buyers is whether this corporate support produces a durable business at the individual pharmacy level.

Pharmaceutical distribution and independent pharmacy retail benefit from long term demographic demand. U.S. pharmaceutical sales are expected to grow at approximately 4.2% annually from 2020 through 2025, while traditional wholesale distribution is expected to grow approximately 3% annually. The biosimilar segment overall is expected to double by 2028. An aging American population uses more prescription medication per person, while pharmaceutical research continues to add new therapies to wholesale and retail channels. Pharmaceuticals represent approximately 10% of overall U.S. healthcare costs. About half of drugs launched globally through 2027 are expected to require cold chain storage, compared with 37% a decade ago. Good Neighbor Pharmacy gives community pharmacies access to the supply chain capabilities of a large pharmaceutical distributor while retaining a local retail presence.

The investment involves converting or establishing a Good Neighbor Pharmacy Premier Pharmacy at a designated site, with Amerisourcebergen Drug Corporation serving as franchisor of record. The program mainly supports existing independent pharmacy operators joining the Good Neighbor Pharmacy network, although it also covers new pharmacies. Public disclosures do not provide specific franchise fees, royalty rates, advertising fund contributions, or liquid capital thresholds. For general healthcare retail context, franchise fees commonly range from $20,000 to $50,000, royalties from 4% to 8% of gross sales, and marketing or advertising contributions from 1% to 5%. These are industry benchmarks, not confirmed terms for this program, so buyers should obtain the current Franchise Disclosure Document from Amerisourcebergen Drug Corporation. Its pharmacy ownership consultants assist buyers and sellers with acquisitions without charging a brokerage fee, while pharmacy acquisition brokerage costs can otherwise range from 5% to 10% of deal value. Buyers should view this opportunity as an institutional affiliation program rather than a standard consumer retail franchise.

Daily operations include prescription dispensing, patient counseling, and management of front end retail categories. Products can include vitamins, cough and cold preparations, first aid supplies, analgesics, and, at select locations, home healthcare products such as canes, walkers, and other durable medical equipment. Amerisourcebergen Drug Corporation supplies medicines and other products on a just in time basis, reducing the need for a standalone warehouse. Amerisourcebergen Pharmacy Ownership Services helps evaluate target locations, analyze total costs, and connect buyers with established banking partners experienced in pharmacy transactions. Franchisees receive a dedicated business coach, and pharmacy acquisition advisors contribute decades of experience. The company maintains a network of thousands of independent pharmacies that can serve as a source of acquisition opportunities. Training through Pharmacy Ownership Services includes hands on transition assistance for new owners, including pharmacists without prior business ownership experience. Public disclosures do not specify exclusive territory rights. Buyers should address territorial protection with Amerisourcebergen Drug Corporation during FDD review, preferably with a franchise attorney.

Cencora held an estimated 30% share of the U.S. pharmaceutical wholesale market in that year, while three firms together controlled over 90% of domestic market revenue. Cencora held a 35% share of the North American specialty medication market as of December 2025, and its biosimilar distribution unit held a leading 30% share among independent distributors focused on biosimilar launches. Consolidated revenue increased from $179.6 billion in fiscal year 2019 to $294.0 billion in fiscal year 2024.

Cencora has committed $1 billion through 2030 to infrastructure, including a 530,000 square foot national distribution center in Harrison, Ohio, scheduled for full operation by spring 2027. The facility will use robotic handling systems, artificial intelligence driven fulfillment, and autonomous mobile robots. A second 430,000 square foot distribution center in Fontana, California is expected to open in fall 2026 and nearly double current West Coast site capacity. Cencora's Dothan, Alabama facility, one of three locations dedicated exclusively to specialty medicines, is undergoing an $80 million expansion expected by fall 2026. The project is expected to increase refrigerated storage capacity by 500% and frozen capacity by 200%. In January 2025, Cencora acquired Retina Consultants of America. In November 2024, Robert P. Mauch became President and CEO, succeeding Steven H. Collis, who had served as Chairman, President, and CEO since becoming president in 2011 and chairman in 2016. Fiscal year 2025 projected revenue is $321 billion. These facilities support the inventory delivery commitments made to affiliated pharmacies, including Good Neighbor Pharmacy Premier locations.

The intended candidate is a licensed pharmacist or pharmacy entrepreneur with retail or community pharmacy experience. Business ownership experience is valued but not required because Pharmacy Ownership Services is designed to support the transition from clinical work to ownership. The program may suit pharmacists leaving salaried roles at large chain pharmacies for ownership of a community pharmacy with national supply chain and marketing support. The acquisition advisory team evaluates markets and locations using patient demographics, competitive density, and projected prescription volume. Multi unit expansion may be available to operators with suitable performance and capitalization, although terms are not publicly disclosed and should be addressed during FDD review. The timeline differs between an acquisition of an existing pharmacy and a new start up location. An existing patient base can accelerate the revenue ramp, while a new pharmacy must build prescription volume from zero. Buyers should work with legal counsel experienced in pharmacy transactions because the process involves franchise law, pharmaceutical licensing, and healthcare real estate.

The Amerisourcebergen Drug Corporation opportunity combines an independent pharmacy's local patient relationships with the procurement, logistics, and support resources of Cencora, a company with $294 billion in revenue, operations across 75 countries, and 51,000 employees. Demand factors include an aging U.S. population, growth in specialty biologics, expanding cold chain requirements, and annual pharmaceutical distribution growth of 3% to 4.2%. The $1 billion infrastructure commitment through 2030, the Harrison, Ohio and Fontana, California distribution centers, the $80 million Dothan expansion, and 12% growth in specialty physician services revenue show continued investment in distribution and specialty care capabilities. PeerSense provides independent franchise research, including SBA lending history, Loan Activity Score, location maps with Google ratings, FDD financial data, and comparison tools for pharmacy and healthcare retail concepts. Buyers can review the complete Amerisourcebergen Drug Corporation franchise profile on PeerSense.